SecBot SecBot
8-K ·Filed Aug 28, 2026

KALA

KALA BIO, Inc.
BEARISH
Impact 8/10
Horizondays Processed2mo ago SEC0001829126-26-009454
8-K context-dependent: Items 3.01
Actionable Insight ▼ Bearish

The delisting risk is acute and the company has no standard compliance path due to the prior reverse split. Monitor for the Nasdaq Hearings Panel decision timeline and any further capital raise or reverse split attempt. The recent $250M ATM offering suggests the company may attempt to raise additional dilutive capital, which would further pressure the stock.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$0.6901
T+0 close · Aug 28, 2026 · via day close
Latest settled
−34.76%
T+20 · $0.4502 · next T+60 in 6d
Vs SPY
−35.02%
α at T+20
Latest observation
−70.39%
T+54 · FF3 residual α
  1. T+0 · Aug 28 $0.6901entry
  2. T+1 · 3mo ago −2.52%α −2.22% · $0.6727
  3. T+5 · 2mo ago −26.49%α −26.60% · $0.5073
  4. T+20 · 7w ago −34.76%α −35.02% · $0.4502
  5. T+55 · todayOpen
  6. T+60 · in 6d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

KALA BIO received a delisting notice from Nasdaq on August 27, 2026, because its stock closed below $1.00 for 30 consecutive business days. The company is ineligible for the standard 180-day compliance period because it already executed a 1-for-50 reverse stock split on May 11, 2026. KALA intends to appeal to a Nasdaq Hearings Panel, which will stay any suspension pending a decision, but the path to regaining compliance is highly uncertain given the company's distressed financial condition and recent massive ATM equity offering.

Key Facts

  • Nasdaq notified KALA on August 27, 2026 that its bid price was below $1.00 for 30 consecutive business days (July 16–August 26, 2026).
  • KALA is ineligible for the standard 180-day compliance period because it effected a 1-for-50 reverse stock split on May 11, 2026.
  • KALA intends to request a hearing before the Nasdaq Hearings Panel to appeal the delisting determination.
  • A timely hearing request will stay any suspension or delisting action pending the Panel's decision.
  • The company previously filed a 424B5 on July 22, 2026 for an ATM offering of up to $250M in common stock, signaling severe financial distress.

Financial Impact

Potential total loss of Nasdaq listing, severely reducing institutional ownership and liquidity for a $16M market cap company with no revenue and no ongoing clinical trials.

liquidityinstitutional ownershipstock price

Risk Factors

  • Nasdaq Hearings Panel may deny continued listing or impose conditions KALA cannot meet
  • No standard 180-day compliance cure period available due to prior reverse split
  • Company has no revenue and no ongoing clinical trials, making a fundamental turnaround unlikely
  • Massive potential dilution from the $250M ATM offering could further depress the stock price

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001829126-26-009454
Document: 0001829126-26-009454-index.html0001829126-26-009454
Document: 0001829126-26-009454.txt0001829126-26-009454

Track record

10 reports on KALA

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +77.78% at T+60 after the Jun 26, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 13, 20263d ago NT 10-Q Bearish 7/10 Entry $0.1496 Now $0.1390 +7.09% settles Nov 17
  2. Nov 12, 20264d ago 8-K Bearish 5/10 Entry $0.1388 to $0.1277 Now $0.1390 −0.14% ▲ +8.02% +6.11% vs SPY
  3. Nov 9, 20267d ago 8-K Neutral 4/10 Entry $0.1773 to $0.1710 Now $0.1390 −21.60% ▼ −3.55% −3.19% vs SPY
  4. Oct 19, 202628d ago SC 13G Neutral 3/10 Entry $0.1926 to $0.1897 Now $0.1390 −27.83% ▼ −1.51% −1.84% vs SPY
  5. Sep 24, 20267w ago Press Release Neutral 3/10 Entry $0.5600 to $0.4760 Now $0.1390 −75.18% ▼ −15.00% −15.54% vs SPY
  6. Aug 28, 202611w ago 8-K Bearish 8/10 Viewing Entry $0.6901 to $0.6727 Now $0.1390 +79.86% ▲ +2.52% +2.22% vs SPY
  7. Jul 22, 202616w ago 424B5 Bearish 8/10 Entry $0.6103 to $0.6342 Now $0.1390 +77.22% ▼ −3.92% −3.81% vs SPY
  8. Jun 26, 202620w ago EFFECT Bearish 7/10 Entry $2.52 to $2.09 Now $0.1390 +94.48% ▲ +17.06% +18.71% vs SPY
  9. May 7, 202627w ago S-3 Neutral 2/10 Entry $3.95 to $3.91 Now $0.1390 −96.48% ▼ −1.01% −1.24% vs SPY
  10. Mar 4, 202636w ago Press Release Mixed 6/10 Entry $17.25 to $0.2750 Now $0.1390 −99.19% ▼ −98.41% −97.83% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 28, 2026